{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:43:06Z","timestamp":1784641386294,"version":"3.55.0"},"posted":{"date-parts":[[2025,12,27]]},"group-title":"Physiology","reference-count":72,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01HL168568"],"award-info":[{"award-number":["R01HL168568"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["F31HL179791"],"award-info":[{"award-number":["F31HL179791"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor (GLP-1R) agonists have recently been suggested as effective therapies to treat or reduce the risk of developing secondary lymphedema in patients with obesity; however, it is unknown whether the observed improvement in lymphatic function is solely due to weight loss-associated systemic benefits or in synergy with a lymphatic-specific effect of these pharmacological therapies.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We assessed the expression and localization GLP-1Rs in and around the lymphatic vasculature by single-cell RNA sequencing and fluorescence confocal microscopy. Using pressure myography we evaluated the direct effects of GLP-1R agonist, semaglutide, on modulating the contractile activity of lymphatic vessels from healthy wild-type (WT) mice, as well as lymphatics from diet-induced obese (DIO) WT mice, and hypercholesterolemic ApoE KO mice.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    Expression of\n                    <jats:italic>Glp1r<\/jats:italic>\n                    (encoding GLP-1Rs) was detected solely in LECs and was highly enriched in LECs from collecting lymphatics but absent in LECs from capillary regions. Pharmacological activation of GLP-1Rs using semaglutide led to robust vasodilation and an increase in the pumping capacity of isolated collecting lymphatics from WT, DIO, and ApoE KO mice. Compared to WT controls, lymphatics from ApoE KO mice displayed significant contractile dysfunction, which was restored with semaglutide. The GLP-1R-mediated response was in part facilitated by nitric oxide (NO), NADPH oxidase-mediated reactive oxygen species (ROS), and potentially vasodilatory prostanoids.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results revealed a direct, beneficial effect of GLP-1R agonism on lymphatic pumping capacity mediated by robust vasodilation, allowing lymphatics to accommodate larger fluid volumes, while maintaining strong and highly efficient contractions. Our observations implicated NO, ROS, and potentially vasodilatory prostanoids in the underlying mechanism; however, additional signaling components remain to be elucidated. These findings support recent clinical reports and further suggest that GLP-1R agonism could be an effective therapy for improving lymphatic contractile function in secondary lymphedema.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2025.12.26.696603","type":"posted-content","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T20:35:12Z","timestamp":1766867712000},"source":"Crossref","is-referenced-by-count":2,"title":["GLP-1R Agonism Directly Improves the Pumping Capacity of Murine Collecting Lymphatic Vessels"],"prefix":"10.64898","author":[{"given":"Mary E.","family":"Schulz","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria L.","family":"Akerstrom","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Dayan","sequence":"additional","affiliation":[{"name":"The Institute for Advanced Reconstruction, Glen Rock, NJ, 07452"},{"name":"The Institute for Lymphatic Surgery & Innovation, Glen Rock, NJ, 07452"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5252-375X","authenticated-orcid":false,"given":"Jorge A.","family":"Castorena-Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025123100050889000_2025.12.26.696603v1.1","unstructured":"Brown S , Campbell AC , Kuonqui K , et al. The Future of Lymphedema: Potential Therapeutic Targets for Treatment. Curr Breast Cancer Rep. 2023:1\u20139."},{"key":"2025123100050889000_2025.12.26.696603v1.2","doi-asserted-by":"crossref","unstructured":"Duhon BH , Phan TT , Taylor SL , Crescenzi RL , Rutkowski JM . Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis. Int J Mol Sci. 2022;23(12).","DOI":"10.3390\/ijms23126621"},{"key":"2025123100050889000_2025.12.26.696603v1.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318307"},{"key":"2025123100050889000_2025.12.26.696603v1.4","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1413.014"},{"key":"2025123100050889000_2025.12.26.696603v1.5","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X9700200408"},{"key":"2025123100050889000_2025.12.26.696603v1.6","unstructured":"Rockson SG. Trial of acebilustat for the treatment of upper arm lymphedema (HEAL). https:\/\/clinicaltrials.gov\/study\/NCT05203835."},{"key":"2025123100050889000_2025.12.26.696603v1.7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-112315-031200"},{"key":"2025123100050889000_2025.12.26.696603v1.8","doi-asserted-by":"crossref","unstructured":"Zhou H , Lei PJ , Padera TP . Progression of Metastasis through Lymphatic System. Cells. 2021;10(3).","DOI":"10.3390\/cells10030627"},{"issue":"11","key":"2025123100050889000_2025.12.26.696603v1.9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11920-024-01543-y","article-title":"Cancer-Related Lymphedema and Psychological Distress","volume":"26","year":"2024","journal-title":"Curr Psychiatry Rep"},{"key":"2025123100050889000_2025.12.26.696603v1.10","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02441-2"},{"issue":"1","key":"2025123100050889000_2025.12.26.696603v1.11","doi-asserted-by":"crossref","first-page":"111e","DOI":"10.1097\/PRS.0000000000002258","article-title":"Diagnosis and Management of Obesity-Induced Lymphedema","volume":"138","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"2025123100050889000_2025.12.26.696603v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1201684"},{"key":"2025123100050889000_2025.12.26.696603v1.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.2009.00855.x"},{"key":"2025123100050889000_2025.12.26.696603v1.14","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000000268"},{"issue":"6","key":"2025123100050889000_2025.12.26.696603v1.15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/lrb.2020.29095.sr","article-title":"The Role of Body Mass Index in Breast Cancer-Associated Lymphedema","volume":"18","year":"2020","journal-title":"Lymphat Res Biol"},{"key":"2025123100050889000_2025.12.26.696603v1.16","doi-asserted-by":"crossref","unstructured":"Sudduth CL , Greene AK . Lymphedema and Obesity. Cold Spring Harb Perspect Med. 2022;12(5).","DOI":"10.1101\/cshperspect.a041176"},{"issue":"7","key":"2025123100050889000_2025.12.26.696603v1.17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/wound.2020.1337","article-title":"Current Overview of Obesity-Induced Lymphedema","volume":"11","year":"2022","journal-title":"Adv Wound Care (New Rochelle"},{"key":"2025123100050889000_2025.12.26.696603v1.18","doi-asserted-by":"crossref","unstructured":"Tsai RJ , Dennis LK , Lynch CF , et al. Lymphedema following breast cancer: The importance of surgical methods and obesity. Front Womens Health. 2018;3(2).","DOI":"10.15761\/FWH.1000144"},{"key":"2025123100050889000_2025.12.26.696603v1.19","first-page":"9234183","article-title":"Disease Specific to Chronic Lymphedema and Class III Obesity","volume":"2020","year":"2020","journal-title":"Case Rep Med"},{"key":"2025123100050889000_2025.12.26.696603v1.20","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199810000-00013"},{"key":"2025123100050889000_2025.12.26.696603v1.21","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0b013e31828bb332"},{"issue":"9","key":"2025123100050889000_2025.12.26.696603v1.22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s42255-021-00457-w","article-title":"Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity","volume":"3","year":"2021","journal-title":"Nat Metab"},{"key":"2025123100050889000_2025.12.26.696603v1.23","doi-asserted-by":"crossref","first-page":"823266","DOI":"10.3389\/fphar.2022.823266","article-title":"Lymphatic Valve Dysfunction in Western Diet-Fed Mice: New Insights Into Obesity-Induced Lymphedema","volume":"13","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025123100050889000_2025.12.26.696603v1.24","doi-asserted-by":"crossref","first-page":"1558763","DOI":"10.3389\/fphys.2025.1558763","article-title":"Chronic metabolic stress impairs lymphatic contractility via activation of KATP channels in a mouse model of Type-2 diabetes","volume":"16","year":"2025","journal-title":"Front Physiol"},{"key":"2025123100050889000_2025.12.26.696603v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05752.x"},{"key":"2025123100050889000_2025.12.26.696603v1.26","first-page":"1098408","article-title":"Multiple aspects of lymphatic dysfunction in an ApoE (-\/-) mouse model of hypercholesterolemia","volume":"13","year":"2022","journal-title":"Front Physiol"},{"key":"2025123100050889000_2025.12.26.696603v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69196-4"},{"key":"2025123100050889000_2025.12.26.696603v1.28","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvv117"},{"key":"2025123100050889000_2025.12.26.696603v1.29","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00664.2015"},{"key":"2025123100050889000_2025.12.26.696603v1.30","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00606.2011"},{"key":"2025123100050889000_2025.12.26.696603v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2018.12.008"},{"key":"2025123100050889000_2025.12.26.696603v1.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094713"},{"key":"2025123100050889000_2025.12.26.696603v1.33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070703"},{"key":"2025123100050889000_2025.12.26.696603v1.34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fphys.2020.00459","article-title":"Regulation of Lymphatic Function in Obesity","volume":"11","year":"2020","journal-title":"Front Physiol"},{"key":"2025123100050889000_2025.12.26.696603v1.35","doi-asserted-by":"crossref","unstructured":"Antoniak K , Hansdorfer-Korzon R , Mrugacz M , Zorena K. Adipose Tissue and Biological Factors. Possible Link between Lymphatic System Dysfunction and Obesity. Metabolites. 2021;11(9).","DOI":"10.3390\/metabo11090617"},{"key":"2025123100050889000_2025.12.26.696603v1.36","doi-asserted-by":"publisher","DOI":"10.1113\/JP271757"},{"key":"2025123100050889000_2025.12.26.696603v1.37","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00244.2014"},{"key":"2025123100050889000_2025.12.26.696603v1.38","doi-asserted-by":"crossref","unstructured":"Emmerich SD , Fryar CD , Stierman B , Ogden CL . Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023. NCHS Data Brief. 2024;(508).","DOI":"10.15620\/cdc\/159281"},{"issue":"1","key":"2025123100050889000_2025.12.26.696603v1.39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jacl.2017.11.006","article-title":"Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins","volume":"12","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"2025123100050889000_2025.12.26.696603v1.40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/advances\/nmaa080","article-title":"Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain","volume":"11","year":"2020","journal-title":"Adv Nutr"},{"key":"2025123100050889000_2025.12.26.696603v1.41","doi-asserted-by":"crossref","unstructured":"Lecis D , Prandi FR , Barone L , et al. Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born? Biomolecules. 2023;13(12).","DOI":"10.3390\/biom13121695"},{"issue":"1","key":"2025123100050889000_2025.12.26.696603v1.42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/03007995.2024.2442027","article-title":"Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials","volume":"41","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"2025123100050889000_2025.12.26.696603v1.43","doi-asserted-by":"crossref","first-page":"10202","DOI":"10.1038\/srep10202","article-title":"Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis","volume":"5","year":"2015","journal-title":"Sci Rep"},{"key":"2025123100050889000_2025.12.26.696603v1.44","doi-asserted-by":"crossref","first-page":"1457363","DOI":"10.3389\/fphar.2024.1457363","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)","volume":"15","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025123100050889000_2025.12.26.696603v1.45","doi-asserted-by":"crossref","first-page":"1392375","DOI":"10.3389\/fonc.2024.1392375","article-title":"GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report","volume":"14","year":"2024","journal-title":"Front Oncol"},{"issue":"6","key":"2025123100050889000_2025.12.26.696603v1.46","first-page":"641","article-title":"Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report","volume":"17","year":"2024","journal-title":"Obes Facts"},{"key":"2025123100050889000_2025.12.26.696603v1.47","doi-asserted-by":"crossref","unstructured":"Schulz ME , Akerstrom VL , Song K , et al. Regulation of Collecting Lymphatic Vessel Contractile Function by TRPV4 Channels. Arterioscler Thromb Vasc Biol. 2025.","DOI":"10.1161\/ATVBAHA.124.322100"},{"key":"2025123100050889000_2025.12.26.696603v1.48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.312576"},{"key":"2025123100050889000_2025.12.26.696603v1.49","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00499.2017"},{"key":"2025123100050889000_2025.12.26.696603v1.50","doi-asserted-by":"crossref","unstructured":"Davis MJ , Kim HJ , Li M , et al. Roles of G-protein coupled receptors and mechanosensitive ion channels in pressure-induced chronotropy of lymphatic vessels. bioRxiv. 2025.","DOI":"10.7554\/eLife.109466"},{"key":"2025123100050889000_2025.12.26.696603v1.51","doi-asserted-by":"crossref","unstructured":"Zawieja SD , Pea GA , Broyhill SE , et al. Cellular characterization of the mouse collecting lymphatic vessels reveals that lymphatic muscle cells are the innate pacemaker cells. Elife. 2025;12.","DOI":"10.7554\/eLife.90679"},{"key":"2025123100050889000_2025.12.26.696603v1.52","doi-asserted-by":"crossref","unstructured":"Castorena-Gonzalez JA , Li M , Davis MJ . Effects of Elevated Downstream Pressure and the Role of Smooth Muscle Cell Coupling through Connexin45 on Lymphatic Pacemaking. Biomolecules. 2020;10(10).","DOI":"10.3390\/biom10101424"},{"key":"2025123100050889000_2025.12.26.696603v1.53","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8712-2_15"},{"key":"2025123100050889000_2025.12.26.696603v1.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42877-6"},{"key":"2025123100050889000_2025.12.26.696603v1.55","doi-asserted-by":"publisher","DOI":"10.1113\/JP279612"},{"key":"2025123100050889000_2025.12.26.696603v1.56","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2006.4.3"},{"key":"2025123100050889000_2025.12.26.696603v1.57","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2012.250662"},{"key":"2025123100050889000_2025.12.26.696603v1.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56953-3"},{"key":"2025123100050889000_2025.12.26.696603v1.59","doi-asserted-by":"crossref","unstructured":"Zawieja SD , Pea GA , Broyhill SE , et al. IP3R1 underlies diastolic ANO1 activation and pressure-dependent chronotropy in lymphatic collecting vessels. J Gen Physiol. 2023;155(12).","DOI":"10.1085\/jgp.202313358"},{"key":"2025123100050889000_2025.12.26.696603v1.60","doi-asserted-by":"crossref","unstructured":"Gonzalez-Loyola A , Bovay E , Kim J , et al. FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure. Sci Adv. 2021;7(29).","DOI":"10.1126\/sciadv.abf4335"},{"key":"2025123100050889000_2025.12.26.696603v1.61","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2007.130401"},{"key":"2025123100050889000_2025.12.26.696603v1.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2010.04.067"},{"key":"2025123100050889000_2025.12.26.696603v1.63","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080963"},{"key":"2025123100050889000_2025.12.26.696603v1.64","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00527.2014"},{"key":"2025123100050889000_2025.12.26.696603v1.65","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1440"},{"issue":"7","key":"2025123100050889000_2025.12.26.696603v1.66","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2025123100050889000_2025.12.26.696603v1.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2018.09.002"},{"key":"2025123100050889000_2025.12.26.696603v1.68","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.739938"},{"key":"2025123100050889000_2025.12.26.696603v1.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.06.009"},{"key":"2025123100050889000_2025.12.26.696603v1.70","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0976"},{"key":"2025123100050889000_2025.12.26.696603v1.71","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1465"},{"key":"2025123100050889000_2025.12.26.696603v1.72","doi-asserted-by":"crossref","first-page":"114339","DOI":"10.1016\/j.ejpb.2024.114339","article-title":"Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats","volume":"200","year":"2024","journal-title":"Eur J Pharm Biopharm"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2025.12.26.696603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:05:15Z","timestamp":1767168315000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2025.12.26.696603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":72,"URL":"https:\/\/doi.org\/10.64898\/2025.12.26.696603","relation":{},"subject":[],"published":{"date-parts":[[2025,12,27]]},"subtype":"preprint"}}